Latest news for ARYx Therapeutics (OTC:ARYX) Stock

ARYx Therapeutics Inc is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with well-established, commercially successful drugs.

Analyst Color

News

Downgrades

Markets

Analyst Ratings

ARYX

Oppenheimer Lowers ARYx Therapeutics (ARYX) To Perform

ARYX THERAPEUTICS INC by ARYx Therapeutics, Inc.

ARYx Therapeutics Inc

Intraday Update

Movers

Trading Ideas

AACAF

AACAY

AAGIY

AAIGF

AAMMF

AAUKF

AAVMY

AAVVF

ABBRF

ABCP

ABILF

ABMC

ABNAF

ABSSF

ACDVF

ACGBY

ARCH BIOPARTNERS INC ORD by Arch Biopartners Inc.

ACHFF

ACKRF

ACNDF

ACNNF

ACOPF

ACRL

ACSAY

ACUIF

ADAD

ADDDF

ADDYY

ADMT

ADYEY

AEGOF

AERG

AETUF

AEXAY

AFLYY

AGCBF

AGESY

AGFAF

AGGFF

AHCHY

AHEXY

ALTERNATE HEALTH CORP ORD by Alternate Health Corp.

AHGIF

AHKSF

AHKSY

AHWSF

AIBGY

AIBRF

AIQUY

AIRRF

AISSF

AJMPF

AJXGF

AKAOQ

AKBTY

AKZOY

ALBY

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

ALFVY

ALIAF

ALIF

Allianz Ag Muenchen Namen-Akt Vinkuliert Shares

ALIZF

ALLVF

ALMTF

ALPMY

ALSMY

ALVOF

ALYI

AMADY

AMAZ

AMBBY

AMIGY

AMKAF

AMKBF

AMKBY

AMLZF

AMMX

AMRQQ

AMXEF

ANEWF

ANGPY

ANPDF

ANPDY

ANSLY

ANTH

ANACONDA MINING INC by Anaconda Mining Inc.

ANXGF

Australia and New Zealand Banking Group Limited

ANZBY

ANZLY

AOIFF

AOMFF

ASCOT RESOURCES LTD by Ascot Resources Ltd.

AOTVF

APELY

APHD

APMCF

AQARF

ARAFF

ARESF

ARGKF

ARKAY

ARNGF

ARREF

ARRRF

Stocks That Hit 52-Week Highs On Tuesday

Oppenheimer downgraded ARYx Therapeutics (NASDAQ: <a class="ticker" href="/stock/aryx#NASDAQ">ARYX</a>) from “outperform” to “perform.” 
Oppenheimer is concerned about ARYX not receiving substantial value for all or part of the company from a potential acquirer. 
ARYX’s shares have slumped 48.24% to close at $1.47.

ARYx Therapeutics

Oppenheimer downgraded ARYx Therapeutics (NASDAQ: <a class="ticker" href="/stock/aryx#NASDAQ">ARYX</a>) from “outperform” to “perform.” 

Oppenheimer is concerned about ARYX not receiving substantial value for all or part of the company from a potential acquirer. 

ARYX’s shares have slumped 48.24% to close at $1.47.

Comments

ARYx Therapeutics

News

Latest news for ARYx Therapeutics (OTC:ARYX) Stock

Tuesday, March 24, 2020

Monday, February 22, 2010

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga